Lobbying Income
—
Filings
89
Unique Clients
1
Active Period
2000–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Improving Seniors’ Timely Access to Care Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3514
Improving Seniors’ Timely Access to Care Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3514
Clinical Trial Modernization Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Issues impacting laboratory testing and pediatric reference intervals (PRIs) Clinical trials regulations and coverage Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034) Clinical Trial Modernization Act (H.R. 3521 / S. 4440)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3521
CONNECT for Health Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 4206
CONNECT for Health Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 4206
Sickle Cell Disease Comprehensive Care Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 5178
Sickle Cell Disease Comprehensive Care Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 5178
Continuing Appropriations and Extensions Act, 2027
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R.9260) FY2027 Continuing Appropriations Act (through 12/04/2026)(H.R. 9770) FY2027 Continuing Appropriations and Extensions Act (through 12/11/2026)(H.R. 6500) OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 6500
Medicare Patient Access and Practice Stabilization Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 879
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R.9260) FY2027 Continuing Appropriations Act (through 12/04/2026)(H.R. 9770) FY2027 Continuing Appropriations and Extensions Act (through 12/11/2026)(H.R. 6500) OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034)
Client expense: $100,000 · Firm income: —
Matched citations: H.R.9260
Improving Access to Transfusion Care for Hospice Patients Act of 2026
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 9703
Continuing Appropriations Act, 2027
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R.9260) FY2027 Continuing Appropriations Act (through 12/04/2026)(H.R. 9770) FY2027 Continuing Appropriations and Extensions Act (through 12/11/2026)(H.R. 6500) OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 9770
Expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: H.Res. 1577
CONNECT for Health Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1261
CONNECT for Health Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1261
Improving Seniors’ Timely Access to Care Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1816
Improving Seniors’ Timely Access to Care Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1816
Improving Access to Transfusion Care for Hospice Patients Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1936
Improving Access to Transfusion Care for Hospice Patients Act of 2025
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: S. 1936
Clinical Trial Modernization Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Issues impacting laboratory testing and pediatric reference intervals (PRIs) Clinical trials regulations and coverage Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034) Clinical Trial Modernization Act (H.R. 3521 / S. 4440)
Client expense: $100,000 · Firm income: —
Matched citations: S. 4440
Sickle Cell Disease Treatment Centers Act of 2026
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 5488
Sickle Cell Care Expansion Act of 2026
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 5489
Sickle Cell Disease Comprehensive Care Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)
Client expense: $100,000 · Firm income: —
Matched citations: S. 721
Sickle Cell Disease Comprehensive Care Act
2026 · third_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: S. 721
Improving Seniors’ Timely Access to Care Act of 2025
2026 · second_quarter · Client: AMERICAN SOCIETY OF HEMATOLOGY
Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)
Client expense: $100,000 · Firm income: —
Matched citations: H.R. 3514
Source: Senate LDA